A joint assessment is a structured information for rapid or full/comprehensive HTAs which is the output of joint production in which 2 or more countries and/or organisations work together to prepare shared products or agreed outcomes (Based on definitions from the HTA Network Strategy (page 24) and the EUnetHTA Recommendations (page 6, footnote 8))
Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. Mostly, ventricular tachycardia and ventricular fibrillation are the underlying aetiology of SCA, which is claimed to be successfully treated by a novel defibrillation therapy, a wearable cardioverter defibrillator (WCD).
The assessment aimed to provide valid data on clinical effectiveness and safety of the WCD. Comparators were chosen based on CE mark indications, recommendations from relevant published clinical guidelines and according to the EUnetHTA guidelines. Furthermore, the project intended to elicit patients’ views on aspects regarding their cardiac disease and the WCD therapy as well as to identify neglected outcomes.
Final version of the assessment was published in December 2016
Below is the documentation provided by the Joint Assessment authoring team: